Patents by Inventor Matthias W. Rath

Matthias W. Rath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230321126
    Abstract: The way the SARS-CoV-2 virus infects the cell is a complex process and comprises four main stages: attachment to the cognate receptor, cellular entry, replication and cellular egress. Targeting binding of the virus to the host receptor in order to prevent its entry has been of particular interest. We tested 56 polyphenols, including plant extracts, brazilin, theaflavin-3,3?-digallate, and curcumin displayed the highest binding with the receptor-binding domain of spike protein, inhibiting viral attachment to the human angiotensin-converting enzyme 2 receptor, and thus cellular entry of pseudo-typed SARS-CoV-2 virions. Both, theaflavin-3,3?-digallate at 25 ?g/ml and curcumin above 10 ?g/ml concentration, showed binding with the angiotensin-converting enzyme 2 receptor reducing at the same time its activity in both cell-free and cell-based assays.
    Type: Application
    Filed: August 13, 2021
    Publication date: October 12, 2023
    Inventor: MATTHIAS W RATH
  • Patent number: 11717013
    Abstract: A micronutrient composition is highly effective in relaxing smooth muscle cells in bronchial cell and uterine cell during a specific disease. The micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9(folate) and vitamin B12, magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of smooth muscle cells important in providing much needed relief to breathe during airway constriction in asthma and uterine smooth muscle cell during premenstrual pain.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: August 8, 2023
    Inventor: Matthias W Rath
  • Publication number: 20230225385
    Abstract: A micronutrient composition is highly effective in relaxing smooth muscle cells in bronchial cell and uterine cell during a specific disease. The micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9 (folate) and vitamin B12 magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of smooth muscle cells important in providing much needed relief to breathe during airway constriction in asthma and uterine smooth muscle cell during premenstrual pain.
    Type: Application
    Filed: November 28, 2022
    Publication date: July 20, 2023
    Inventor: MATTHIAS W RATH
  • Patent number: 11679096
    Abstract: The Basic Mix or Mix 1 or Mix 2 comprises of a combination of a Vitamin C (Ca ascorbate) 10 mg-100,000 mg, Vitamin E (D-alpha-tocopherol) 1 mg-3,000 mg, Vitamin B5 1 mg-20,000 mg, Vitamin B6 1 mg-1,000 mg, Folic acid 1 mcg-3,000 mcg, Iodine (Kelp) 1 mcg-2,000 mcg, Selenium 1 mcg-2,000 mcg, Choline 1 mg-5,000 mg, Inositol 1 mg-5000 mg, Phosphatidyl serine 1 mg-1,500 mg, Soy extract containing Daidzein 1 mg-1,500 mg, Glycitein 0.1 mg-1,000 mg, and Genistein 1 mg-2,500 mg, Red clover 1 mg-1,500 mg, Rosemary extract 1 mg-6,000 mg and Chaste tree berry (Vitex agnus-castus) 1 mg-2,000 mg. Mix 1 is effective in repressing the transcription of ApoE gene in fibroblast cells. The formulations counters specific pathology markers, alleviates markers associated with increased risk of degenerative problems (i.e. Alzheimer's disease).
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: June 20, 2023
    Inventor: Matthias W Rath
  • Patent number: 11666643
    Abstract: A micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of vascular smooth muscle cells important in maintaining healthy blood pressure.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: June 6, 2023
    Inventor: Matthias W Rath
  • Patent number: 11654131
    Abstract: A basic mix or Mix 1 or Mix 2 is highly effective in treating estrogen related complications in females. The estrogen related diseases such as cancer are also treated if they are Apo E based manifestations. The basic mix or Mix 1 or Mix 2 comprises of a combination of a Vitamin C (Ca ascorbate) 10 mg-100,000 mg, Vitamin E (D-alpha-tocopherol) 1-3,000 mg, Vitamin B5 1-20,000 mg, Vitamin B6 1-1,000 mg, Folic acid 1-3,000 mcg, Iodine (Kelp) 1-2,000 mcg, Selenium 1-2,000 mcg, Choline 1-5,000 mg, Inositol 1-5000 mg, Phosphatidyl serine 1-1,500 mg, Daidzein 1-1,500 mg, Glycitein 0.1-1,000 mg, Genistein 1-2,500 mg, Red clover 1-1,500 mg, Rosemary extract 1-6,000 mg and Chaste tree berry (Vitex agnus-castus) 1-2,000 mg. The treatment by administering Mix 1 decreases estrogen dependent breast cancer cells proliferation and decrease in expression of cancer promoting cellular markers in cancer cells (iNOS, ApoE).
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: May 23, 2023
    Inventor: Matthias W Rath
  • Patent number: 11571468
    Abstract: A micronutrient composition is highly effective in controlling high blood pressure while given to mammal for treating with or without prescribed pharmaceutical drug. The micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12 and calcium and magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of vascular smooth muscle cells important in maintaining healthy blood pressure. The combined effects of the micronutrients contained in the micronutrient composition include increased production of NO “relaxing factor” and decreased activity of Angiotensin converting enzyme 1 (ACE1). ACE1 inhibitory effect of this natural formula was more pronounced than obtained with the pharmaceutical ACE1 inhibitor—Lisinopril—the commonly prescribed high blood pressure medication.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: February 7, 2023
    Inventor: Matthias W Rath
  • Publication number: 20220304976
    Abstract: A method of preventing, inhibiting and treating a mammal suffering from viral infections using a pharmaceutical micronutrient composition including mixture D is disclosed. The middle east respiratory syndrome-related coronavirus and severe acute respiratory syndrome-related coronavirus as well as their variants and mutants affecting mammals and causing infection are successfully treated using mixture D. Mixture D contains key micronutrients such as an ascorbate, N-acetylcysteine, theaflavins, resveratrol, cruciferous plant extracts, curcumin, quercetin, naringenin, and baicalin and a combination thereof. Mixture D and seemed to have beneficial effects to prevent and treat diseases where viruses use the angiotensin converting enzyme 2 (ACE2) receptor on the surface of epithelial cells, endothelial cells and other cell types for viral entry.
    Type: Application
    Filed: April 25, 2022
    Publication date: September 29, 2022
    Inventor: MATTHIAS W RATH
  • Patent number: 11452710
    Abstract: The micronutrient and plant extract composition comprises of a vitamin C, vitamin A (?-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methylsulfonylmethane (MSM) and stinging nettle extract and in combination it is used for treating, and reversing bone demineralization. The micronutrient and plant extract composition when administered to mammal with or without bone disease strengthens and helps in bone mineralization process. The composition can be used as a preventive dose for bone demineralization in human.
    Type: Grant
    Filed: February 17, 2022
    Date of Patent: September 27, 2022
    Inventor: Matthias W Rath
  • Patent number: 11419847
    Abstract: Pharmaceutical micronutrient composition including mixture D in this study helps to mitigate, inhibit, prevent and stop diseases caused by viral infections. The middle east respiratory syndrome-related coronavirus and severe acute respiratory syndrome-related coronavirus as well as their variants and mutants affecting mammals and causing infection are successfully treated using mixture D. Mixture D contains key micronutrients such as an ascorbate, N-acetylcysteine, theaflavins, resveratrol, cruciferous plant extracts, curcumin, quercetin, naringenin, and baicalin and a combination thereof. Additional micronutrients were tested with Mixture D and seemed to have beneficial effects.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: August 23, 2022
    Inventor: Matthias W Rath
  • Publication number: 20220241386
    Abstract: A micronutrient composition is highly effective in controlling high blood pressure while given to mammal for treating with or without prescribed pharmaceutical drug. The micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12 and calcium and magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of vascular smooth muscle cells important in maintaining healthy blood pressure. The combined effects of the micronutrients contained in the micronutrient composition include increased production of NO “relaxing factor” and decreased activity of Angiotensin converting enzyme 1 (ACE1). ACE1 inhibitory effect of this natural formula was more pronounced than obtained with the pharmaceutical ACE1 inhibitor—Lisinopril—the commonly prescribed high blood pressure medication.
    Type: Application
    Filed: January 19, 2022
    Publication date: August 4, 2022
    Inventor: MATTHIAS W RATH
  • Patent number: 11351148
    Abstract: A threefold decrease in ?-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A shows significant effect on increased insulin secretion and glucose uptake by cells.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: June 7, 2022
    Inventor: Matthias W Rath
  • Patent number: 11337959
    Abstract: A threefold decrease in ?-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix B shows significant effect on increased insulin secretion and glucose uptake by cells.
    Type: Grant
    Filed: December 26, 2021
    Date of Patent: May 24, 2022
    Inventor: Matthias W Rath
  • Patent number: 11304921
    Abstract: A pharmaceutical composition of micronutrients were tried to improve brain health and nervous system functions. Combination of L-theanine, Rhodiola rosea, Acetyl L-Carnitine (ALCAR), Bacopa monnieri, Mucuna pruriens, NAD+, Rose hips extract (trans-tiliroside), American Ginseng, Pyrroloquinoline quinone, Gotu Kola in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: April 19, 2022
    Inventor: Matthias W Rath
  • Patent number: 11304922
    Abstract: A pharmaceutical composition of micronutrients were tried to improve cognitive brain function, brain health and nervous system functions. Combination consisting of Avena sativa (green oat straw extract), Coenzyme Q10, NAD+, American Ginseng, and Pyrroloquinoline quinone in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: April 19, 2022
    Inventor: Matthias W Rath
  • Publication number: 20220047545
    Abstract: The way the SARS-CoV-2 virus infects the cell is a complex process and comprises four main stages: attachment to the cognate receptor, cellular entry, replication and cellular egress. Targeting binding of the virus to the host receptor in order to prevent its entry has been of particular interest. We tested 56 polyphenols, including plant extracts, brazilin, theaflavin-3,3?-digallate, and curcumin displayed the highest binding with the receptor-binding domain of spike protein, inhibiting viral attachment to the human angiotensin-converting enzyme 2 receptor, and thus cellular entry of pseudo-typed SARS-CoV-2 virions. Both, theaflavin-3,3?-digallate at 25 ?g/ml and curcumin above 10 ?g/ml concentration, showed binding with the angiotensin-converting enzyme 2 receptor reducing at the same time its activity in both cell-free and cell-based assays.
    Type: Application
    Filed: August 13, 2021
    Publication date: February 17, 2022
    Inventor: MATTHIAS W RATH
  • Patent number: 11246855
    Abstract: A threefold decrease in ?-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A and Mix B applied together with VitaminD+K2 shows significant effect on increased insulin secretion and glucose uptake by cells.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: February 15, 2022
    Inventor: Matthias W Rath
  • Patent number: 11234952
    Abstract: A pharmaceutical composition of micronutrients were tried to improve brain health and nervous system functions. Various combinations of formulas were used. Formulas 12, 10 and 5 shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: February 1, 2022
    Inventor: Matthias W Rath
  • Publication number: 20220023256
    Abstract: A threefold decrease in ?-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A and Mix B applied together with VitaminD+K2 shows significant effect on increased insulin secretion and glucose uptake by cells.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Inventor: MATTHIAS W. RATH
  • Publication number: 20210315858
    Abstract: The study shows that ascorbic acid and its combination with some natural compounds could be included in developing preventive and therapeutic approaches toward the current pandemic. Some natural compounds were effective in lowering ACE2 cellular expression, with the highest inhibitory effects observed for baicalin (75%) and theaflavin (50%). Significantly, combinations of these and other test compounds with ascorbic acid further decreased ACE2 expression. The highest impact of ascorbate on ACE2 expression was noted when combined with theaflavin (decrease from 50% to 87%), zinc aspartate (decrease from 22% to 62%), and with 10-undecenoic acid (from 18% to 53%). Our study provides valuable experimental confirmation of the efficacy of micronutrients in controlling ACE2 expression—the coronavirus cellular “entry” point. It further validates the importance of nutrient interactions in various aspects of cellular metabolism and in considering potential therapeutic applications of nutrient-based approaches.
    Type: Application
    Filed: March 9, 2021
    Publication date: October 14, 2021
    Inventor: MATTHIAS W RATH